The abdominal aortic aneurysm treatment market is expected to register a modest growth rate of 5.82% through the forecast period, rising in valuation from US$ 2.06 Bn in 2022 to US$ 3.63 Bn in 2032.
| Attributes | Details |
|---|---|
| Market Valuation (2022) | US$ 2.06 billion |
| Market Valuation (2032) | US$ 3.63 billion |
| CAGR | 5.82% |
The abdominal aortic aneurysm treatment market could expand as a result of:
An abdominal aortic aneurysm is the enlargement of the lower part of the aorta in the abdomen. The aorta is the main supplier of blood to the body, hence the ruptured abdominal aortic aneurysm may cause abnormal bleeding. An abdominal aortic aneurysm is an asymptomatic disorder unless there is a rupture which leads to internal bleeding and haemorrhaging.
The treatment of abdominal aortic aneurysms depends upon the size and enlargement of the aorta. Surgical intervention is advised if the aneurysm is larger than 55mm and occurs in people aged above 55 years. It is very rare in people of less than 60 years of age which provides significant evidence that this is an age-related condition.
High cholesterol and blood pressure, diabetes, obesity, and smoking also play an important role in the growing incidence of abdominal aortic aneurysms in people. The disorder is normally detected and diagnosed through an ultrasound of the abdomen but more detailed information can be provided by other modalities such as computed tomography scans for situations where the location of the aneurysm is critical.
A mortality rate is around 75% is estimated if an aneurysm ruptures and causes internal bleeding
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
There is currently no FDA-approved therapy for limiting the growth of an abdominal aortic aneurysm. If the aneurysm is less than 5 cm or 2 inches in diameter, the doctor may first try to treat it with medication. They may prescribe drugs to lower blood pressure and relax blood vessels, such as beta-blockers and calcium channel blockers. These medications will reduce the likelihood of an aneurysm rupture. Indeed, several therapeutic effects of pharmacological agents have been reported in animal models, and some agents have been tested in humans.
Treatment of abdominal aortic aneurysms with statins, angiotensin-converting enzyme inhibitors, antibiotics, and anti-inflammatory agents appears to slow the rate of growth in humans. The doctor will continue to check on the patient on a regular basis to see if the aneurysm is growing. Heavy lifting that puts pressure on the aorta should be avoided. Treatment for specific abdominal aortic aneurysms is based on age, overall health, medical history, the extent of the disease, signs and symptoms, tolerance to specific medications, procedures, or therapies, expectations for the disease's course, and opinion or preference.
Geographically, North America has the largest market share due to the rising prevalence of atherosclerosis. Furthermore, increased research and development is boosting the market growth. Europe is also expected to see an increase in the burden of cardiovascular disease, as well as increased market participant initiatives to expand its product distribution network. Due to rising awareness of advanced treatment options and market players' increased focus on emerging economies, Asia-Pacific is expected to account for the largest market share.
Principal Consultant
To address the current unmet needs in the abdominal aortic aneurysm treatment market and to provide better treatment options, several major pharmaceutical companies are working hard to develop new Abdominal Aortic Aneurysm emerging devices such as the Abdominal Aortic Aneurysm Stent Graft System (Lifetech Scientific), Fenestrated AlturaTM FEVAR Stent Graft (Lombard Medical), Seta Latecba Stent Grafts (Latecba SA The therapeutic options available in the Abdominal Aortic Aneurysm (AAA) landscape aim to reduce disease burden. There are numerous novel Abdominal Aortic Aneurysm devices in development, including -
On September 30, 2018, Lifetech Scientific launched a clinical trial to assess the safety and efficacy of the AAA Stent Graft System for infrarenal abdominal aortic aneurysms.
Endologix LLC, a vascular disease treatment leader, is developing the ChEVAS system, an endovascular abdominal aortic aneurysm therapy that combines the Nellix 3.5 endograft with parallel visceral stents to treat juxta-renal, pararenal, and suprarenal abdominal aortic aneurysms.
The incidence rate of abdominal aortic aneurysm is found to be increasing worldwide due to changes in lifestyle. Abdominal aortic aneurysm occurs commonly in men, four times more than in women.
The risk factors associated with abdominal aortic aneurysm are hypovolemic shock with low blood pressure and elevated heart rate due to which the awareness about the treatment is increasing.
The major factors facilitating the growth of abdominal aortic aneurysm treatment market are increase in geriatric population, increased incidence of hypertension and hyperlipidemia. The restraints of abdominal aortic aneurysm treatment market are cost of treatment and availability of treatment.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
It is estimated that approximately 13,000 deaths occur yearly in U.S. due to abdominal aortic aneurysm rupture in the patients between 60 and 70 years of age. The frequency of disorder is much high in case of smokers as compared to that of non-smokers.
In the U.S. the incidence rate of abdominal aortic aneurysm is estimated to be approximately 2-4% of the adult population. Surgery is advised to patients of abdominal aortic aneurysms, young patients are advised to open surgery and geriatric patient are advised endovascular aneurysms.
Thus, the market for surgeries is expected to contribute majorly in the overall abdominal aortic aneurysm treatment market.
Geographically, the global abdominal aortic aneurysm treatment is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa. North America is expected to be the highly lucrative market for abdominal aortic aneurysm treatment owing to the increased incidence rate of abdominal aortic aneurysms.
European countries are expected to contribute further to the global abdominal aortic aneurysm market in regard to the high geriatric population. However, the investment of the pharmaceutical industries in the R&D of drugs for the treatment of abdominal aortic aneurysms is expected to fuel the growth of the global abdominal aortic aneurysm treatment market.
Some of the key players in the abdominal aortic aneurysm treatment market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers, Abbott, AbbVie Inc., Celgen Corporation, Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc.,Sanofi, GlaxoSmithKline Pharmaceuticals Limited and Mylan N.V.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The global abdominal aortic aneurysm treatment market has been classified on the basis of treatment, end use and geography.
Explore Healthcare Insights
View Reports
Abdominal Aortic Aneurysm Treatment Market
